A recent in vitro study shows that the synthesis of lipid droplet and the proliferation and migration of prostate cancer cells activated by the PPARγ pathway can be effectively promoted by low-dose rosiglitazone (59). This evidence concerns the gene PPARG and prostate carcinoma.